Document is current
Any future updates will be listed below
-
Authors
Herring, Sarah K.
Rodgers, Buel D. https://orcid.org/0000-0003-0751-1105
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R44CA221539)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R44AG079825)
- License Information
-
More Information
Article History
Received: 5 May 2025
Revised: 13 October 2025
Accepted: 30 October 2025
First Online: 19 November 2025
Competing interests
: B.D.R. is the Founder, CEO and majority stock owner of Aavogen, Inc., which develops the proprietary gene therapeutic for muscle wasting (AVGN7.2) that is discussed herein. S.K.H. directs Aavogen’s preclinical development and regulatory affairs and has no financial interests to disclose.
: Animal experiments were performed by Myologica LLC in leased vivarium and laboratory space at the University of Maryland Baltimore and by Sinclair Research (now Altasciences). All mice were housed in environmentally controlled rooms and provided food and water ad libitum . Housing and use were conducted in accordance to animal use protocols preapproved by the respective institutional animal care and use committees and according to National Institutes of Health guidelines. Additional detail is provided in the Supplemental Methods.
